| Cash Flow | 2025-07-31 |
|---|---|
| Net loss for the year | -26,556,140 |
| Amortization | 15,271 |
| Financial income (expenses), net | 56,473 |
| Depreciation | 91,356 |
| Share-based compensation | 776,879 |
| Share of loss on equity investment | -224,212 |
| Change in fair value of the warrant liability | -758,364 |
| Decrease (increase) in amounts receivable | -733,629 |
| Decrease in prepaid expenses | -492,279 |
| (decrease) increase in accounts payable | -3,887,078 |
| Increase (decrease) in accrued expenses and other payables | 753,909 |
| Net cash used in operating activities | -28,170,520 |
| Purchase of short-term investments, net | 7,316,000 |
| Equity investment in bc therapeutics | 330,000 |
| Net cash used in investing activities | -7,646,000 |
| Proceeds from exercise of warrants | 821,015 |
| Proceeds from issuance of shares, net of issuance costs | 44,627,224 |
| Net cash provided by financing activities | 45,448,239 |
| Increase in cash and cash equivalents | 9,631,719 |
| Cash and cash equivalents at beginning of period | 862,089 |
| Cash and cash equivalents at end of period | 10,493,808 |
BriaCell Therapeutics Corp. (BCTX)
BriaCell Therapeutics Corp. (BCTX)